Vamikibart

Monoclonal antibody

Also known as RG6179, RO7200220

Phase 3Mechanism not established
Filedunder review

Evidence outlook · regulatory review

Uveitic Macular Edema: application under FDA review, decision date 2027-07

FDA accepts vamikibart BLA for UME (2026-10-10). A filing is the sponsor's claim that its evidence supports approval; this platform grades the trials, not the filing. The event is listed under Regulatory events.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Uveitic Macular Edema
NCT05642325 · Hoffmann-La Roche
2023-03-23 – 2025-12-24 · Uveitic Macular Edema
What this study did
NCT05642312 · Hoffmann-La Roche
2023-01-09 – 2025-07-09 · Uveitic Macular Edema
What this study did
Phase 2 (2)
Other / comorbidity
NCT05151731 · Hoffmann-La Roche
2021-12-31 – 2025-04-21 · Diabetic Macular Edema
What this study did
NCT05151744 · Hoffmann-La Roche
2021-12-17 – 2024-10-01 · Diabetic Macular Edema
What this study did
Phase 1 (1)
Uveitic Macular Edema
NCT06771271 · Hoffmann-La Roche
2019-07-22 – 2023-11-13 · Diabetic Macular Edema, Uveitic Macular Edema
What this study did

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

July 2027FDA action dateFDA decision expected by July 2027
US, FDA · Source ↗

Recent

10 October 2026Filing acceptedFDA accepts vamikibart BLA for UME
US, FDA · Source ↗